Alaunos Therapeutics, Inc. (TCRT)

Market Cap	5.86M +22.1%
Revenue (ttm)	3,000 -72.7%
Net Income	-4.22M
EPS	-2.07
Shares Out	2.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,097
Open	2.450
Previous Close	2.370
Day's Range	2.400 - 2.550
52-Week Range	1.670 - 6.200
Beta	-1.13
Analysts	Hold
Price Target	205.50 (+8,391.74%)
Earnings Date	May 15, 2026

About TCRT

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 1
• Stock Exchange: NASDAQ
• Ticker Symbol: TCRT
• Website: https://www.alaunos.com

Financial Performance

In 2025, Alaunos Therapeutics's revenue was $5,000, a decrease of -50.00% compared to the previous year's $10,000. Losses were -$4.28 million, -8.48% less than in 2024.

Analyst Summary

According to one analyst, the rating for TCRT stock is "Hold" and the 12-month stock price target is $205.5.

Price Target

$205.5

(8,391.74% upside)

Analyst Consensus: Hold